In this cohort study of 274 patients with metastatic ERBB2-positive breast cancer and CNS metastasis, those with CNS-only disease had longer overall survival and a lower risk of death from any cause compared with patients with concomitant extracranial metastases. This evidence concerns the gene ERBB2 and breast cancer.